ReviewBiomolecules2026
Challenges and Opportunities in Multi-Omics Data Acquisition and Analysis: Toward Integrative Solutions.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mapping the path to clinical implementation of multi-omics.Nature genetics · 2026Review
- Multi-omics profiling of pancreatic neuroendocrine tumors: Interplay of genomic instability and the tumor microenvironment (Review).Oncology letters · 2026Review
- Article
- Beyond the 'Pregnancy Black Box': a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health.The pharmacogenomics journal · 2026Review
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- From empirical vaccinology to predictive systems-based vaccine design: multi-omics integration, artificial intelligence, and global equity challenges.Frontiers in systems biology · 2026Review
- Proteomic signals are not equal clinical phenotypes: redefining evidence standards in arbovirus-SARS-CoV-2 cross-reactivity.Frontiers in immunology · 2026Review
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
- Integrative Bioinformatics Approaches in Environmental Biotechnology: A Review.TheScientificWorldJournal · 2026Review
- Advancing Drug Discovery with AI: Machine and Deep Learning Strategies for Target Identification and Precision Nanomedicine.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In this perspective, we discuss the current challenges and opportunities in multi-omics, a rapidly evolving approach that integrates multiple molecular layers to advance our understanding of complex biological systems. As biomedical research moves toward precision medicine, the ability to correlate genotype, phenotype, and environmental contexts has never been more critical. Multi-omics enhances biomarker discovery and elucidates regulatory networks underlying health and disease. The dominant scientific paradigm for over a century was to take a reductionist approach, studying individual molecular components in isolation or as simplified systems. The advent of omics technologies in the 1990s enabled a systems paradigm, allowing holistic analyses of molecular networks. These early systems studies were constrained by technology and methodology to bulk tissue measurements and single-omics analyses. Recent advances in single-cell and spatial omics, high-throughput proteomics and metabolomics, cloud computing, and artificial intelligence now allow high-resolution, spatially contextualized multi-omics analyses. Despite these gains, challenges in data analysis and interpretation remain, including high dimensionality, missing or incomplete data, multiple batch effects, and method-specific variability. Emerging strategies-such as paired data collection, staged or joint integration, and latent factor or quasi-mediation frameworks-offer promising solutions, positioning multi-omics as a transformative tool for elucidating complex mechanisms and guiding personalized medicine. Continued refinement of these approaches may further enhance the utility of multi-omics for understanding complex biological systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.